ClinicalTrials.gg
Not yet recruitingNCT07729371FAPUpdated Aug 12, 2026

A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).

A Phase 1 interventional study of ST316 IV and ST316 IV in Familial Adenomatous Polyposis (FAP), sponsored by Sapience Therapeutics. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Sapience Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1b, open- label, dose-optimization study evaluating ST316 in adult participants with familial adenomatous polyposis (FAP) who have undergone colectomy and have recurrent polyps. This study uses a three-cohorts, sequential adaptive design to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ST316, as well as its preliminary efficacy in reducing polyp recurrence.

02

Conditions studied

  • Familial Adenomatous Polyposis (FAP)

Keywords

  • Familial adenomatous polyposis
  • FAP
  • Polyp recurrence
  • Colorectal polyps
  • Colectomy
  • Hereditary colorectal cancer
  • Desmoid tumors
03

In context

Adenomatous Polyposis Coli

92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 61 interventional studies indexed under Adenomatous Polyposis Coli.

Browse Adenomatous Polyposis Coli studies →

Lead sponsor

Sapience Therapeutics is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 years or older at the time of .
  2. Ability to understand and willingness to sign a written informed consent document, prior to undertaking any study-related procedures.
  3. Confirmed Familial Adenomatous Polyposis (FAP) by molecular genetic testing and at least six polyps of 5-9 mm. Patients with FAP that present thyroid nodule and/ or desmoid tumors are eligible.
  4. History of prophylactic colectomy with either ileo-rectal anastomosis (IRA) or ileal pouch-anal anastomosis (IPAA), performed at least 12 months prior to screening, and without ongoing surgical complications.
  5. Presence of rectal/pouch polyps at baseline; polyps must be \<10 mm in size. If polyps ≥10 mm are identified during the baseline colonoscopy, they must be endoscopically removed at the time of the baseline colonoscopy before first dose of ST316.
  6. Willingness to forgo concurrent use of supplements containing, turmeric, omega-3 fatty acids, oral , NSAIDs, or other FAP-directed drug therapy for the duration of the study. Low-dose aspirin (80-100 mg daily) for cardioprotective indications will be permitted.
  7. Adequate organ function as defined by ALL of the following laboratory criteria (obtained within 28 days prior to first dose):

    Total ≤1.5 × institutional (unless Gilbert's syndrome). Alkaline phosphatase ≤1.5 × institutional ULN. (SGOT) ≤1.5 × institutional ULN. ALT (SGPT) ≤1.5 × institutional ULN. Serum creatinine ≤1.5 × institutional ULN.

  8. Women of (WOCBP) and male participants who are sexually active with WOCBP must agree to use highly effective from screening throughout study duration and for at least 90 days after last dose.
  9. Not currently breastfeeding. Women must agree not to breastfeed from first dose through 90 days after last dose.

Exclusion criteria

Exclusion Criteria:

  1. Use of any other agent or participation in an interventional clinical trial within 12 weeks prior to first dose of ST316.
  2. Receipt of systemic oral within 30 days prior to first dose of ST316.
  3. Uncontrolled intercurrent illness or recent (within 4 weeks) major surgical procedure (excluding disease-related surgery, which should be >12 months from screening) that would limit compliance or pose undue risk to the participant.
  4. History of invasive within 3 years prior to screening (exceptions: carcinoma of the cervix in situ, carcinoma in situ of any site, or basal/squamous cell carcinoma of the skin that has been completely excised).
  5. Concurrent use of anticoagulants with a risk of bleeding that may preclude study-related procedures (i.e., endoscopy and ).
  6. Use of other NSAIDs (e.g., ibuprofen) exceeding 4 days per month, within 6 weeks prior to first dose of ST316.
  7. Regular use of aspirin at doses exceeding 700 mg per week.
  8. Treatment with other FAP-directed drug therapy (including sulindac, celecoxib, or fish oil) within 4 weeks prior to first dose of ST316.
  9. Any of the following findings on baseline biopsy obtained during screening colonoscopy:

    1. Colorectal cancer on biopsy.
    2. Duodenal cancer on biopsy.
    3. High-grade dysplasia found on polyp biopsy where the polyp has not been completely removed.
    4. A large polyp (>1 cm) not completely removed at baseline colonoscopy.
  10. >480 ms before first dose of ST316.
  11. Significant medical or psychiatric disorder that would preclude study participation or capacity.
  12. Known to ST316 or any of its .
  13. Currently pregnant, breastfeeding, or planning to conceive during the projected duration of the study (including 90 days post-last dose).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Cohort 1 will be ST316 2mg/kg IV once weekly (QW) for 26 weeks

    Drug: ST316 IV

  • Experimental
    Cohort 2

    Cohort 2 will be ST316 2mg/kg IV once every three weeks

    Drug: ST316 IV

  • Experimental
    Cohort 3

    Cohort 3 will be ST316 6mg/kg IV once weekly (QW) for 26 weeks

    Drug: ST316 IV

Interventions

  • DrugST316 IV

    ST316 will be administered as an IV weekly

  • DrugST316 IV

    ST316 will be administered once every 3 weeks

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Related Adverse Events By CTCAE V5.0 Severity Grade

    Numbers and percentage of participants with treatment-related adverse events as assessed by severity grade (CTCAE V5); incidence of SAEs;

    Time frame: From first dose through 30 days after last dose

  2. Percentage change from Baseline in Colorectal/ Pouch Poly Burden (Sum in Diameters) at Month 6

    Percentage change from baseline to Month 6 in the sum of diameters of colorectal/ pouch and duodenal polyp burden (sum in diameters) as assessed by endoscopy

    Time frame: 1 year

Secondary outcomes

  1. Percentage change

    Percentage change from baseline in colorectal/ pouch polyp burden and polyp count at month 3 and 9

    Time frame: 1 year

  2. Dose optimization

    Dose optimization will be assessed for further development

    Time frame: 1 year

  3. Regrowth of Polyps

    Regrowth of polyps from excised/ tattooed areas will be assessed

    Time frame: 1 year

  4. New or Increased Polyp size

    New or increased polyp size amenable for resection greater than 10mm

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 27, 2026
StartEst.
Jan 4, 2027
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07729371
Lead sponsor
Sapience Therapeutics
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Jan 4, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Aug 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion